WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Nevirapine pharmacokinetics are affected by several factors including CYP2B6 single nucleotide polymorphisms (SNPs). These genetic profiles are more common in African patients and they affect the drug clearance being associated with higher trough concentrations. Pharmacokinetic/pharmacogenetic (PK/PG) studies are difficult to perform in remote areas where refrigeration is not available, although dried plasma and dried blood methods have been validated. WHAT THIS STUDY ADDS: • Dried plasma spots are useful tools for studying nevirapine PK with a good association to plasma concentrations and they can be used in rural areas since a cold chain is not necessary. Dried blood spots can be used to store and analyze patients' DNA for PG polymorphisms. Nevirapine trough concentrations in Burundese patients, not studied so far, are above the target concentration (3000 ng ml(-1) ) in 84% of patients. CYP2B6 (both at position 516 and 983) but not ABCB1 (3435 and 1236) SNPs as well as age correlate with higher nevirapine exposure. AIMS: The pharmacokinetics (PK) and pharmacogenetics (PG) of nevirapine have been studied in rich and limited-resource countries. CYP2B6 single nucleotide polymorphisms (SNPs) have been associated with decreased drug clearance. We evaluated the PG determinants of nevirapine trough concentrations in a rural cohort in Burundi using easy to store and transport dried sample spot devices. METHODS: A cross-sectional analysis in HIV-positive nevirapine-treated patients in Kiremba, north of Burundi, was performed in 2009. After blood withdrawal whole blood was stored on dried blood spots and plasma (after centrifugation) was placed on dried plasma spot devices and stored at room temperature. Nevirapine plasma and dried sample spot concentrations were compared to test the clinical usefulness of this method. SNPs in CYP2B6 and ABCB1 (using a real time PCR technique) were analyzed and associated with nevirapine plasma trough concentrations. RESULTS: Nevirapine concentrations measured on dried plasma spot devices were highly related to plasma concentrations in 60 patients, although a negative bias was observed (-18%). Nevirapine trough concentrations were above the target concentration (3000 ng ml(-1) ) in 84% of patients and they were associated with CYP2B6 SNPs (both at position 516 and 983). No effect of ABCB1 SNPs was noted. CONCLUSIONS: Dried plasma spot devices are accurate tools for measuring nevirapine concentrations in rural settings where refrigeration is not available, despite a moderate underestimation bias. They allowed the evaluation of nevirapine concentrations in a cohort of HIV-infected people in rural Burundi, confirming very good exposure and correlation with PG polymorphisms in the CYP2B6 encoding gene.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: • Nevirapine pharmacokinetics are affected by several factors including CYP2B6 single nucleotide polymorphisms (SNPs). These genetic profiles are more common in African patients and they affect the drug clearance being associated with higher trough concentrations. Pharmacokinetic/pharmacogenetic (PK/PG) studies are difficult to perform in remote areas where refrigeration is not available, although dried plasma and dried blood methods have been validated. WHAT THIS STUDY ADDS: • Dried plasma spots are useful tools for studying nevirapine PK with a good association to plasma concentrations and they can be used in rural areas since a cold chain is not necessary. Dried blood spots can be used to store and analyze patients' DNA for PG polymorphisms. Nevirapine trough concentrations in Burundesepatients, not studied so far, are above the target concentration (3000 ng ml(-1) ) in 84% of patients. CYP2B6 (both at position 516 and 983) but not ABCB1 (3435 and 1236) SNPs as well as age correlate with higher nevirapine exposure. AIMS: The pharmacokinetics (PK) and pharmacogenetics (PG) of nevirapine have been studied in rich and limited-resource countries. CYP2B6 single nucleotide polymorphisms (SNPs) have been associated with decreased drug clearance. We evaluated the PG determinants of nevirapine trough concentrations in a rural cohort in Burundi using easy to store and transport dried sample spot devices. METHODS: A cross-sectional analysis in HIV-positivenevirapine-treated patients in Kiremba, north of Burundi, was performed in 2009. After blood withdrawal whole blood was stored on dried blood spots and plasma (after centrifugation) was placed on dried plasma spot devices and stored at room temperature. Nevirapine plasma and dried sample spot concentrations were compared to test the clinical usefulness of this method. SNPs in CYP2B6 and ABCB1 (using a real time PCR technique) were analyzed and associated with nevirapine plasma trough concentrations. RESULTS:Nevirapine concentrations measured on dried plasma spot devices were highly related to plasma concentrations in 60 patients, although a negative bias was observed (-18%). Nevirapine trough concentrations were above the target concentration (3000 ng ml(-1) ) in 84% of patients and they were associated with CYP2B6 SNPs (both at position 516 and 983). No effect of ABCB1 SNPs was noted. CONCLUSIONS: Dried plasma spot devices are accurate tools for measuring nevirapine concentrations in rural settings where refrigeration is not available, despite a moderate underestimation bias. They allowed the evaluation of nevirapine concentrations in a cohort of HIV-infected people in rural Burundi, confirming very good exposure and correlation with PG polymorphisms in the CYP2B6 encoding gene.
Authors: D González de Requena; S Bonora; S Garazzino; M Sciandra; A D'Avolio; R Raiteri; R Marrone; M Boffito; F G De Rosa; A Sinicco; G Di Perri Journal: Antimicrob Agents Chemother Date: 2005-09 Impact factor: 5.191
Authors: Jörg Zukunft; Thomas Lang; Tanja Richter; Karen I Hirsch-Ernst; Andreas K Nussler; Kathrin Klein; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger Journal: Mol Pharmacol Date: 2005-02-18 Impact factor: 4.436
Authors: Lisa M Almond; Damitha Edirisinghe; Mark Dalton; Alec Bonington; David J Back; Saye H Khoo Journal: Clin Pharmacol Ther Date: 2005-08 Impact factor: 6.875
Authors: Mina C Hosseinipour; Amanda H Corbett; Cecelia Kanyama; Idah Mshali; Severiano Phakati; Nazer L Rezk; Charles van der Horst; Angela D M Kashuba Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: Alessandro Schipani; Christoph Wyen; Tabitha Mahungu; Heidy Hendra; Deirdre Egan; Marco Siccardi; Gerry Davies; Saye Khoo; Gerd Fätkenheuer; Michael Youle; Jürgen Rockstroh; Norbert H Brockmeyer; Margaret A Johnson; Andrew Owen; David J Back Journal: J Antimicrob Chemother Date: 2011-03-25 Impact factor: 5.790
Authors: Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti Journal: Pharmgenomics Pers Med Date: 2022-06-21
Authors: Imke H Bartelink; Rada M Savic; Julia Mwesigwa; Jane Achan; Tamara Clark; Albert Plenty; Edwin Charlebois; Moses Kamya; Sera L Young; Monica Gandhi; Diane Havlir; Deborah Cohan; Francesca Aweeka Journal: J Clin Pharmacol Date: 2013-09-21 Impact factor: 3.126
Authors: Carine Nguefeu Nkenfou; Barbara Atogho Tiedeu; Celine Nguefeu Nkenfou; Akindeh M Nji; Jean Paul Chedjou; Calvino Tah Fomboh; Charles Kouanfack; Wilfred F Mbacham Journal: Appl Clin Genet Date: 2019-12-30